Murine liver organoids as a genetically flexible system to study liver cancer in vivo and in vitro
The rising incidence of cholangiocarcinoma (CCA) coupled with a low 5-year survival rate that remains below 10% delineates the urgent need for more effective treatment strategies. Although several recent studies provided detailed information on the genetic landscape of this fatal malignancy, versati...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
05 February 2019
|
| In: |
Hepatology communications
Year: 2019, Jahrgang: 3, Heft: 3, Pages: 423-436 |
| ISSN: | 2471-254X |
| DOI: | 10.1002/hep4.1312 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/hep4.1312 Verlag, lizenzpflichtig, Volltext: https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep4.1312 
|
| Verfasserangaben: | Anna Saborowski, Katharina Wolff, Steffi Spielberg, Benedikt Beer, Björn Hartleben, Zulrahman Erlangga, Diana Becker, Lukas E. Dow, Silke Marhenke, Norman Woller, Kristian Unger, Peter Schirmacher, Michael P. Manns, Jens U. Marquardt, Arndt Vogel, and Michael Saborowski |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1694269590 | ||
| 003 | DE-627 | ||
| 005 | 20220818033800.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200408s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hep4.1312 |2 doi | |
| 035 | |a (DE-627)1694269590 | ||
| 035 | |a (DE-599)KXP1694269590 | ||
| 035 | |a (OCoLC)1341314286 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Saborowski, Anna |d 1981- |e VerfasserIn |0 (DE-588)134222571 |0 (DE-627)563029390 |0 (DE-576)30038579X |4 aut | |
| 245 | 1 | 0 | |a Murine liver organoids as a genetically flexible system to study liver cancer in vivo and in vitro |c Anna Saborowski, Katharina Wolff, Steffi Spielberg, Benedikt Beer, Björn Hartleben, Zulrahman Erlangga, Diana Becker, Lukas E. Dow, Silke Marhenke, Norman Woller, Kristian Unger, Peter Schirmacher, Michael P. Manns, Jens U. Marquardt, Arndt Vogel, and Michael Saborowski |
| 264 | 1 | |c 05 February 2019 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 03.07.2020 | ||
| 520 | |a The rising incidence of cholangiocarcinoma (CCA) coupled with a low 5-year survival rate that remains below 10% delineates the urgent need for more effective treatment strategies. Although several recent studies provided detailed information on the genetic landscape of this fatal malignancy, versatile model systems to functionally dissect the immediate clinical relevance of the identified genetic alterations are still missing. To enhance our understanding of CCA pathophysiology and facilitate rapid functional annotation of putative CCA driver and tumor maintenance genes, we developed a tractable murine CCA model by combining the cyclization recombination (Cre)-lox system, RNA interference, and clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) technology with liver organoids, followed by subsequent transplantation into immunocompetent, syngeneic mice. Histologically, resulting tumors displayed cytokeratin 19-positive ductal structures surrounded by a desmoplastic stroma—hallmark features of human CCAs. Despite their initial biliary phenotype in vitro, organoids retained the plasticity to induce a broader differentiation spectrum of primary liver cancers following transplantation into recipient mice, depending on their genetic context. Thus, the organoid system combines the advantage of using nontransformed, premalignant cells to recapitulate liver tumorigenesis as a multistep process, with the advantage of a reproducible and expandable cell culture system that abrogates the need for recurrent isolations of primary cells. Conclusion: Genetically modified liver organoids are able to transform into histologically accurate CCAs. Depending on the oncogenic context, they are also able to give rise to liver cancers that show features of hepatocellular carcinomas. The model can be used to functionally explore candidate cancer genes of primary liver cancers in immunocompetent animals and evaluate novel treatment regimens. | ||
| 700 | 1 | |a Schirmacher, Peter |d 1961- |e VerfasserIn |0 (DE-588)1020440112 |0 (DE-627)691221197 |0 (DE-576)360427448 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hepatology communications |d [Alphen aan den Rijn] : Wolters Kluwer Health, 2017 |g 3(2019), 3, Seite 423-436 |h Online-Ressource |w (DE-627)877444587 |w (DE-600)2881134-3 |w (DE-576)482132256 |x 2471-254X |7 nnas |a Murine liver organoids as a genetically flexible system to study liver cancer in vivo and in vitro |
| 773 | 1 | 8 | |g volume:3 |g year:2019 |g number:3 |g pages:423-436 |g extent:14 |a Murine liver organoids as a genetically flexible system to study liver cancer in vivo and in vitro |
| 856 | 4 | 0 | |u https://doi.org/10.1002/hep4.1312 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep4.1312 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200408 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1020440112 |a Schirmacher, Peter |m 1020440112:Schirmacher, Peter |d 910000 |d 912000 |e 910000PS1020440112 |e 912000PS1020440112 |k 0/910000/ |k 1/910000/912000/ |p 12 | ||
| 999 | |a KXP-PPN1694269590 |e 362060102X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1694269590"],"doi":["10.1002/hep4.1312"]},"physDesc":[{"extent":"14 S."}],"relHost":[{"disp":"Murine liver organoids as a genetically flexible system to study liver cancer in vivo and in vitroHepatology communications","recId":"877444587","language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["Volume 1, Issue 1 (2017)-"],"corporate":[{"display":"American Association for the Study of Liver Diseases","role":"isb"}],"origin":[{"dateIssuedKey":"2017","publisherPlace":"[Alphen aan den Rijn] ; Hoboken, NJ","publisher":"Wolters Kluwer Health ; Wiley","dateIssuedDisp":"2017-"}],"name":{"displayForm":["American Association for the Study of Liver Diseases"]},"title":[{"title_sort":"Hepatology communications","title":"Hepatology communications"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"text":"3(2019), 3, Seite 423-436","volume":"3","year":"2019","pages":"423-436","extent":"14","issue":"3"},"id":{"eki":["877444587"],"zdb":["2881134-3"],"issn":["2471-254X"]},"note":["Gesehen am 19.01.23"]}],"note":["Gesehen am 03.07.2020"],"recId":"1694269590","name":{"displayForm":["Anna Saborowski, Katharina Wolff, Steffi Spielberg, Benedikt Beer, Björn Hartleben, Zulrahman Erlangga, Diana Becker, Lukas E. Dow, Silke Marhenke, Norman Woller, Kristian Unger, Peter Schirmacher, Michael P. Manns, Jens U. Marquardt, Arndt Vogel, and Michael Saborowski"]},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"05 February 2019"}],"person":[{"family":"Saborowski","display":"Saborowski, Anna","given":"Anna","role":"aut"},{"family":"Schirmacher","given":"Peter","display":"Schirmacher, Peter","role":"aut"}],"language":["eng"],"title":[{"title":"Murine liver organoids as a genetically flexible system to study liver cancer in vivo and in vitro","title_sort":"Murine liver organoids as a genetically flexible system to study liver cancer in vivo and in vitro"}]} | ||
| SRT | |a SABOROWSKIMURINELIVE0520 | ||